Source: International Congress 2014 – The story continues: impact of OSA on cardiometabolic parameters
Disease area: Sleep and breathing disorders

Abstract

Background Hypoxia, sympathetic activation, vascular endothelial dysfunction, metabolic dysregulation, oxidative stress as well as inflammation play a role in the development of cardiovascular disease in OSAS and are related to the release of vasopressin (AVP). We hypothesize that AVP might serve as a potential proxy for prognosis and therapy response in OSAS.Methods 289 patients with suspicion of OSAS undergoing a diagnostic work-up were included in this prospective, interventional, longitudinal, case-control study. The primary endpoint was the change in AVP levels after 1 month of CPAP treatment. Secondary endpoints included 1) circulating AVP levels before treatment and after 1 and 6 months of treatment respectively; 2) change in circulating AVP levels after 1 night and 6 months of CPAP treatment respectively; 3) assessment of endpoints in subgroups of patients according to OSAS severity.Results 243 patients with OSAS (age 55.0 ± 13.0 years, 77.8 % male, BMI 31.2 ± 5.6) and 46 controls without OSAS (age 51.2 ± 14.2 years, 50 % male, BMI 30.7 ± 5.8) were analysed. Mean ODI of patients with OSAS was 18 / h ± 15, mean AHI was 17 / h ± 15. 87.9 % of patients with OSAS started cPAP therapy. After 1 month, 85.1 % of patients with OSAS were on cPAP therapy. There was no significant difference in the slope of change of the AVP level between patients and controls and between OSAS patients with or without CPAP therapy. After adjustment for severity of OSAS, comorbidities and duration of CPAP therapy in minutes the differences remained non-statistically significant.Conclusions Vasopressin cannot be used as a proxy for prognosis and therapy response in obstructive sleep apnoea syndrome.

Rating:

Share or cite this content

Citations should be made in the following way:
P. Grendelmeier, W. Strobel, T. Schmid, K. Jahn, M. Tamm, D. Stolz (Basel, Solothurn, Switzerland). Vasopressin in patients with obstructive sleep apnoea syndrome – An interventional, case-control study. Eur Respir J 2014; 44: Suppl. 58, 1747

Member's Comments

No comment yet.

Related content which might interest you: Prevalence of hyperuricemia in patients with obstructive sleep apnea from the Mallorca cohort Source: International Congress 2014 – The story continues: impact of OSA on cardiometabolic parameters Year: 2014 Response to exercise in patients with obstructive sleep apnea Source: International Congress 2014 – Sleep disordered breathing 5 Year: 2014 Obstructive sleep apnoea syndrome and a calculation of cardiovascular risk Source: International Congress 2014 – The story continues: impact of OSA on cardiometabolic parameters Year: 2014 The efficacy of oral appliance in patients with severe obstructive sleep apnea Source: International Congress 2014 – Sleep disordered breathing 2 Year: 2014 Evaluation of lipid profile in patients with obstructive sleep apnea syndrome Source: International Congress 2015 – To treat or not to treat? Sleep-disordered breathing II Year: 2015 Elevated risk of motor vehicle accidents in patients with obstructive sleep apnea syndrome: A case-control study Source: Annual Congress 2013 –Sleep disordered breathing in special situations II Year: 2013 A novel postal-based approach to diagnosing obstructive sleep apnoea in a high risk population Source: International Congress 2014 – Sleep disordered breathing 1 Year: 2014 Acromegaly screening in patients with sleep apnea symptoms Source: International Congress 2014 – Sleep disordered breathing 1 Year: 2014 Translational medicine in obstructive sleep apnea Source: International Congress 2014 – Sleep disordered breathing 3 Year: 2014 Phenotyping comorbidity in obstructive sleep apnea syndrome Source: International Congress 2015 – Measuring sleep-disordered breathing in children and adults II: questionnaires, epidemiology and sleep studies Year: 2015 Transition from obstructive sleep apnea (OSA) to obesity hypoventilation syndrome (OHS) Source: International Congress 2015 – Measuring sleep-disordered breathing in children and adults I: questionnaires, epidemiology and sleep studies Year: 2015 Obstructive sleep apnoea and hypothyroidism Source: International Congress 2015 – Measuring sleep-disordered breathing in children and adults II: questionnaires, epidemiology and sleep studies Year: 2015 Relationship between hepcidin levels and periodic limb movements in sleep in patients with obstructive sleep apnea syndrome Source: International Congress 2014 – Sleep disordered breathing 1 Year: 2014 Erythrocytosis in patients with obstructive sleep apnea Source: International Congress 2014 – Sleep disordered breathing 1 Year: 2014 Familial aggregation of obstructive sleep apnoea in children without tonsillar hypertrophy Source: International Congress 2014 – Three ages of man: OSA in children, adults and the elderly Year: 2014 Libido disorders in patients with obstructive sleep apnea Source: International Congress 2014 – Sleep disordered breathing: from children to the elderly Year: 2014 Predictors of nocturnal hypertension in obstructive sleep apnea patients with metabolic syndrome Source: Annual Congress 2013 –A metabolic medley: sleep disordered breathing Year: 2013 Microalbuminuria in obstrucive sleep apnea syndrome Source: International Congress 2014 – The story continues: impact of OSA on cardiometabolic parameters Year: 2014 Gender differences in comorbidity burden in recently diagnosed obstructive sleep apnea patients Source: International Congress 2014 – Sleep disordered breathing 1 Year: 2014 Clinical validation of a novel FOT-based APAP device for treatment of obstructive sleep apnea Source: International Congress 2015 – To treat or not to treat, and how? Sleep-disordered breathing I Year: 2015